27235977|t|Laser -facilitated epicutaneous immunotherapy to IgE-mediated allergy
27235977|a|Allergen specific immunotherapy has been shown to be the only effective treatment for long-lasting clinical benefit to IgE-mediated allergic diseases, but a fewer than 5% of patients choose the treatment because of inconvenience and a high risk of anaphylaxis. Recently, epicutaneous allergen-specific immunotherapy (EPIT) has proven effective, yet with limitations owing to strong skin reactions. We demonstrate here safer and faster EPIT, named μEPIT, by delivering powdered allergen and adjuvants into many micropores in the epidermis. We fabricated a microarray patch fractionally coated with a powder mixture of ovalbumin (OVA) model allergen, CpG, and 1,25-dihydroxyvitamin D3 (VD3). Topical application of the patch onto laser-microperforated skin resulted in a high level of epidermal delivery while greatly minimizing allergen leakage into circulation system as compared to current subcutaneous immunotherapy (SCIT). Moreover, only three times of μEPIT over two weeks could sufficiently inhibit allergen-specific IgE responses in mice suffering OVA -induced airway hyperresponsivness (AHR), which was unattainable by eight times of SCIT over three weeks. Mechanistically, μEPIT preferably enhanced IgG2a production suggesting TH1-biased immune responses and induced a high level of T-regulatory (Treg) cells against repeated allergen sensitization. The immune tolerance was confirmed by marked reduction in airway wall thickness as well as eosinophil and neutrophil infiltration into the respiratory airway. The μEPIT represents a novel and painless technology to treat IgE-mediated allergic diseases with little local skin reaction and a minimal risk of anaphylaxis.
27235977	19	31	epicutaneous	T058	UMLS:C0001558
27235977	32	45	immunotherapy	T058	UMLS:C0021083
27235977	49	69	IgE-mediated allergy	T038	UMLS:C1706410
27235977	70	101	Allergen specific immunotherapy	T058	UMLS:C0162352
27235977	142	151	treatment	T058	UMLS:C0087111
27235977	189	219	IgE-mediated allergic diseases	T038	UMLS:C1706410
27235977	264	273	treatment	T058	UMLS:C0087111
27235977	305	317	high risk of	T033	UMLS:C0332167
27235977	318	329	anaphylaxis	T038	UMLS:C0002792
27235977	341	385	epicutaneous allergen-specific immunotherapy	T058	UMLS:C0162352
27235977	387	391	EPIT	T058	UMLS:C0162352
27235977	445	466	strong skin reactions	T201	UMLS:C0221743
27235977	505	509	EPIT	T058	UMLS:C0162352
27235977	517	522	μEPIT	T058	UMLS:C0162352
27235977	538	555	powdered allergen	T103	UMLS:C0002092
27235977	560	569	adjuvants	T103	UMLS:C0001551
27235977	580	590	micropores	T017	UMLS:C1325742
27235977	598	607	epidermis	T017	UMLS:C0014520
27235977	636	641	patch	T074	UMLS:C0991556
27235977	669	696	powder mixture of ovalbumin	T103	UMLS:C0029923
27235977	698	701	OVA	T103	UMLS:C0029923
27235977	709	717	allergen	T103	UMLS:C0002092
27235977	719	722	CpG	T103	UMLS:C0056912
27235977	728	752	1,25-dihydroxyvitamin D3	T103	UMLS:C0006674
27235977	754	757	VD3	T103	UMLS:C0006674
27235977	787	792	patch	T074	UMLS:C0991556
27235977	798	819	laser-microperforated	T033	UMLS:C1709025
27235977	820	824	skin	T022	UMLS:C1123023
27235977	853	862	epidermal	T017	UMLS:C0014520
27235977	897	905	allergen	T103	UMLS:C0002092
27235977	906	913	leakage	T033	UMLS:C4281748
27235977	919	937	circulation system	T022	UMLS:C0007226
27235977	961	987	subcutaneous immunotherapy	T058	UMLS:C0413381
27235977	989	993	SCIT	T058	UMLS:C0413381
27235977	1026	1031	μEPIT	T058	UMLS:C0162352
27235977	1074	1095	allergen-specific IgE	T103	UMLS:C0443736
27235977	1109	1113	mice	T204	UMLS:C0025929
27235977	1124	1127	OVA	T103	UMLS:C0029923
27235977	1137	1162	airway hyperresponsivness	T038	UMLS:C0035228
27235977	1164	1167	AHR	T038	UMLS:C0035228
27235977	1211	1215	SCIT	T058	UMLS:C0413381
27235977	1251	1256	μEPIT	T058	UMLS:C0162352
27235977	1277	1282	IgG2a	T103	UMLS:C0020857
27235977	1283	1293	production	T038	UMLS:C0003261
27235977	1305	1315	TH1-biased	T017	UMLS:C0242632
27235977	1316	1332	immune responses	T038	UMLS:C0301872
27235977	1361	1373	T-regulatory	T017	UMLS:C0039198
27235977	1375	1379	Treg	T017	UMLS:C0039198
27235977	1381	1386	cells	T017	UMLS:C0007634
27235977	1404	1426	allergen sensitization	T038	UMLS:C2938930
27235977	1432	1448	immune tolerance	T038	UMLS:C0020963
27235977	1473	1482	reduction	T058	UMLS:C0441610
27235977	1486	1497	airway wall	T017	UMLS:C0458827
27235977	1498	1507	thickness	T033	UMLS:C0205400
27235977	1519	1529	eosinophil	T017	UMLS:C0014467
27235977	1534	1557	neutrophil infiltration	T038	UMLS:C0751982
27235977	1567	1585	respiratory airway	T017	UMLS:C0282335
27235977	1591	1596	μEPIT	T058	UMLS:C0162352
27235977	1643	1648	treat	T058	UMLS:C0087111
27235977	1649	1679	IgE-mediated allergic diseases	T038	UMLS:C1706410
27235977	1692	1711	local skin reaction	T201	UMLS:C0221743
27235977	1734	1745	anaphylaxis	T038	UMLS:C0002792